2014;90(3):518
‑
25.
9.
Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, et al.
Neurocognitive function and progression in patients with brain metastases treated with
whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
J Clin Oncol Off J Am Soc Clin Oncol. 1 janv 2004;22(1):157
‑
65.
10.
Sneed PK, Mendez J, Vemer-van den Hoek JGM, Seymour ZA, Ma L, Molinaro AM,
et al. Adverse radiation effect after stereotactic radiosurgery for brain metastases:
incidence, time course, and risk factors. J Neurosurg. août 2015;123(2):373
‑
86.
11.
Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al.
Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a
multi-institutional prospective observational study. Lancet Oncol. avr
2014;15(4):387
‑
95.
12.
Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, et al. Lapatinib
plus capecitabine in patients with previously untreated brain metastases from HER2-
positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet
Oncol. janv 2013;14(1):64
‑
71.
13.
Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of
memory with conformal avoidance of the hippocampal neural stem-cell compartment
during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-
institutional trial. J Clin Oncol Off J Am Soc Clin Oncol. 1 déc 2014;32(34):3810
‑
6.
14.
Sun B, Huang Z, Wu S, Shen G, Cha L, Meng X, et al. Incidence and relapse risk of
intracranial metastases within the perihippocampal region in 314 patients with breast
cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 7 déc 2015;
